David C. Linch

35.4k citations

358 papers · 20.9k indexed · 6 hit papers · h-index 74

Impact in

Hematology top 0.02%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 154
- Acute Myeloid Leukemia Research 72
- Hematopoietic Stem Cell Transplantation 66
Genetics 97
- Chronic Lymphocytic Leukemia Research 44
- Myeloproliferative Neoplasms: Diagnosis and Treatment 31

Co-authors: Rosemary E. Gale Alan K. Burnett Anthony H. Goldstone Robert K. Hills Panagiotis Kottaridis A. H. Goldstone Asim Khwaja Rajesh Chopra
Journals: British Journal of Haematology (99 papers)Blood (79 papers)Journal of Clinical Oncology (22 papers)The Lancet (11 papers)British Journal of Cancer (6 papers)
Partner nations: United Kingdom United States Australia

In The Last Decade

David C. Linch

357 papers receiving 20.3k citations

Hit Papers

6 papers align trajectories log scale

Acute myeloid leukaemia 2016 · 289 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 Nature Reviews Disease Primers
2013 The Lancet
2010 Journal of Clinical Oncology
2007 Blood
2001 Blood
1993 The Lancet

Peers

Countries citing papers authored by David C. Linch

Since Specialization

Citations

This map shows the geographic impact of David C. Linch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David C. Linch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David C. Linch more than expected).

Fields of papers citing papers by David C. Linch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David C. Linch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David C. Linch. The network helps show where David C. Linch may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David C. Linch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David C. Linch Line = papers co-authored together David C. Linch links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Therapy for isocitrate dehydrogenase 2 (IDH2)^R172‐mutant acute myeloid leukaemia British Journal of Haematology ·David C. Linch, Robert K. Hills, Alan K. Burnett, Nigel H. Russell, Rosemary E. Gale	2021	2
2	EZH2 -Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication Stress Cancer Discovery ·Theresa E. León, Benn Steil, Cosetta Bertoli, Sunniyat Rahman, Michael Magnussen, Brian Philip, Nadine Farah, Simon Richardson, Sara Ahrabi, José Afonso Guerra‐Assunção, Rajeev Gupta, Elisabeth P. Nacheva, Stephen Henderson, Javier Herrero, David C. Linch, Robertus A.M. de Bruin, Marc R. Mansour	2020	22
3	Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial SHILAP Revista de lepidopterología ·Elizabeth H. Phillips, Catherine Burton, Amy A. Kirkwood, Sharon Barrans, 観浦西, Simon Rule, Russell Patmore, Ruth Pettengell, Kirit M. Ardeshna, Silvia Montoto, Shankara Paneesha, Laura Clifton‐Hadley, David C. Linch, Andrew McMillan	2020	6
4	Evaluation of the Safety and Tolerability of Rapid Infusion of Biosimilar Rituximab Truxima® — the University College London Hospitals (UCLH) Experience Blood ·Susumu Yamada, Fitriani Indahsari, Kirit M. Ardeshna, Kate Cwynarski, David C. Linch, Andres Virchis, Jonathan Lambert, Christopher McNamara, William Townsend	2017	3
5	Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era Journal of Clinical Oncology ·Christian Gisselbrecht, Bertram Glaß, Nicolas Mounier, Devinder Gill, David C. Linch, Marek Trněný, André Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg, Dávid Ma, Josette Brière, Craig H. Moskowitz, Norbert Schmitz Hit paper breakdown →	2010	1117
6	In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm Blood ·Jonathan Lambert, Tamara Everington, David C. Linch, Rosemary E. Gale	2009	29
7	Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244 Journal of Clinical Oncology ·Peter Hoskin, Lisa Lowry, Alan Horwich, Andrew Jack, 片岡利枝子, Barry W. Hancock, Paul Smith, Wendi Qian, 纪树荣, Bilyana Popova, Andrew R. Pettitt, David Cunningham, Ruth Pettengell, John Sweetenham, David C. Linch, Peter Johnson	2009	124
8	Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study Leukemia & lymphoma ·Kurt Hampe, David C. Linch, Wendi Qian, 椎奈今立, John F. Seymour, Paul Smith, Lindsey Stevens, Simon Rule	2009	20
9	A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft Leukemia & lymphoma ·Kirsty Thomson, Karl S. Peggs, Desak Gede Pradnyani Paramitha, Anthony H. Goldstone, David C. Linch	2007	11
10	Hodgkin's lymphoma The Lancet ·Lynny Yung, David C. Linch	2003	157
11	Debate on the conservative and aggressive treatment options for the optimal management of indolent non-Hodgkinʼs lymphoma Anti-Cancer Drugs ·Kevin Imrie, David C. Linch, Myron S. Czuczman	2002	6
12	Influence of cell cycling and cell division on transendothelial migration of CD34⁺ cells British Journal of Haematology ·Kwee Yong, I Putu Brawisia Wicaksana, Arnold Pizzey, David C. Linch	2002	16
13	Allogeneic transplantation following failure of autologous transplantation for lymphoma. UCL Discovery (University College London) ·(unknown), Panagiotis Kottaridis, (unknown), Julie M. Vose, David C. Linch, Stephen Mackinnon, Michael R. Bishop, Steven Z. Pavletic, Marc Freeman, Anthony P. Goldstone, (unknown)	1998	3
14	Acquired skewing of X‐chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age British Journal of Haematology ·Rosemary E. Gale, Adele K. Fielding, Claire Harrison, David C. Linch	1997	190
15	The regulation of neutrophil phospholipase A₂ by granulocyte‐macrophage colony‐stimulating factor and its role in priming superoxide production British Journal of Haematology ·Pamela Roberts, Siôn L. Williams, David C. Linch	1996	14
16	Pyrimethamine in the myeloproliferative disorders: a forgotten treatment? Clinical & Laboratory Haematology ·Stella Bowcock, David C. Linch, Samuel J. Machin, J W Stewart	1987	6
17	Investigations of the simian ontogenic switch from fetal to adult hemoglobin at the progenitor cell level. Journal of Clinical Investigation ·B P Alter, RS Weinberg, David C. Linch, Catherine Glynn, Benjamin T. Jackson, George J. Piasecki, Kuljinder S. Chase, David G. Nathan	1986	1
18	A rise in the percentage of large unstained cells in the peripheral blood determined by the Hemalog D90 automated differential counter is a feature of impending myeloid engraftment following bone marrow transplantation Clinical & Laboratory Haematology ·Philippe Martin, Charles C. Anderson, H.M. Jones, A. A. Trushnikov, David C. Linch, A. H. Goldstone	1986	9
19	PRENATAL DIAGNOSIS OF IMMUNODEFICIENCY DISORDERS British Medical Bulletin ·David C. Linch, R J Levinsky	1983	8
20	Acquired Pure Red-Cell Aplasia Associated with an Increase of T Cells Bearing Receptors for the Fc of IgG Acta Haematologica ·David C. Linch, John C. Cawley, S.M. MacDonald, Eric Yang, B. E. Roberts, A.H. Antonis, Simone Girardi Andrade, Colin A. Sieff, Peter M. Lydyard	1981	45

About David C. Linch

David C. Linch is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Oncology and Immunology, having authored 358 papers that have together received 20.9k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (123 papers), Acute Myeloid Leukemia Research (72 papers), Hematopoietic Stem Cell Transplantation (66 papers), Viral-associated cancers and disorders (50 papers), Chronic Lymphocytic Leukemia Research (44 papers), Acute Lymphoblastic Leukemia research (37 papers), CNS Lymphoma Diagnosis and Treatment (31 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (31 papers). The work is most often cited by research in Hematology (8.9k citations), Genetics (4.9k citations), Pathology and Forensic Medicine (6.6k citations), Oncology (7.0k citations) and Immunology (3.7k citations). David C. Linch has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Rosemary E. Gale, Alan K. Burnett, Anthony H. Goldstone, Robert K. Hills, Panagiotis Kottaridis, A. H. Goldstone, Asim Khwaja, Rajesh Chopra, Barry W. Hancock and David Cunningham. Their work appears in journals such as British Journal of Haematology, Blood, Journal of Clinical Oncology, The Lancet and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact